RPG Life Sciences Ltd (RPGLIFE) — Announcement | 15 September 2026

· BSE Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
RPG Life Sciences completes API business transfer via slump sale
💡 Investor Takeaway
Shareholders gain a stronger, more focused pharmaceutical business with expanded API capabilities.

RPG Life Sciences announced completion of its subsidiary's business transfer agreement with Raghava Life Sciences Private Limited, effective September 16, 2026, transferring API and intermediates businesses via slump sale. This strategic move strengthens RPG Life Sciences' pharmaceutical portfolio and market positioning.

📄 View Original Announcement (PDF)

About RPG Life Sciences Ltd (RPGLIFE)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹4,509.45 Cr P/E: 37.7 ROE: 19.8% ROCE: 25.8% Div Yield: 0.88%

View full RPGLIFE stock details →

📡 Get AI alerts when RPGLIFE files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track RPGLIFE — Free

📊 More RPGLIFE filings

See all RPGLIFE filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when RPGLIFE files new disclosures

Track RPGLIFE filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track RPGLIFE — Free

Free account · 2 AI queries/day